Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
Becton, Dickinson and Company (BD) announced early tender results for its cash tender offers on senior notes due 2022 and 2023, with a total maximum cap of $1.285 billion. As of August 18, 2021, $877.6 million of the 2.894% senior notes and $128.1 million of the 3.300% senior notes were tendered. The company plans to redeem any untendered 2.894% notes by September 13, 2021. The tender offers will lead to early settlements on August 20, 2021, with a prorated acceptance for certain notes exceeding their tender caps.
BD (Becton, Dickinson and Company) (NYSE: BDX) has announced the launch of the BD FACSymphony™ A1 Cell Analyzer, a benchtop system designed to enhance access to flow cytometry capabilities for laboratories of all sizes. This fluorescence-activated cell analyzer features advanced research capabilities and compact design, enabling efficient resource use and time-saving for researchers. The device supports various experiments from small particle studies to 16-color immunophenotyping, utilizing BD's industry-standard software for streamlined workflows.
BD (Becton, Dickinson and Company) has appointed Christopher DelOrefice as the new chief financial officer (CFO), effective Sept. 6, 2021, following Christopher Reidy's planned retirement. DelOrefice previously held key finance positions at Johnson & Johnson, contributing nearly two decades of experience in healthcare finance. His expertise will aid BD in executing its 2025 growth strategy and boosting shareholder value. DelOrefice's vast background, including roles in Investor Relations, positions him as a strong asset for BD's leadership team.
Becton, Dickinson and Company (NYSE: BDX) announced an amendment to its tender offers for certain Senior Notes due 2024. The maximum principal amount for its 3.734% Senior Notes has been increased from $300 million to $500 million, while the total maximum for all offered notes rises from $715 million to $1.285 billion. Other terms remain unchanged. The tender offers are outlined in the Offer to Purchase, dated August 5, 2021, which investors should carefully review for full details.
Becton, Dickinson and Company (NYSE: BDX) announced tender offers to purchase cash for its outstanding debt securities totaling up to $715 million. The offers include senior notes due in 2022 and 2023, along with specific notes due in 2024, with an emphasis on early tender payments for participants before the August 18 deadline. The tender offers will expire on September 1, 2021, or as extended. The company retains the right to increase tender cap limits and emphasizes the need for interested holders to review the Offer to Purchase for comprehensive details.
BD reported a strong third fiscal quarter, with revenues reaching $4.9 billion, a 26.9% increase year-over-year. COVID-19 testing revenues contributed $300 million, including $212 million from the BD Veritor™ Plus System. The GAAP diluted EPS surged 77.3% to $1.72, while adjusted diluted EPS grew 24.5% to $2.74. BD raised its fiscal 2021 revenue growth and adjusted EPS guidance, projecting revenue growth of 16.5% to 17.0% and adjusted EPS between $12.85 and $12.95.
BD (Becton, Dickinson and Company) announced the retirement of Christopher Reidy, its CFO and CAO, effective after a successor is appointed. Reidy, who joined BD in 2013, will transition to a director role at the upcoming independent Diabetes Care company after its expected spinoff in early 2022. During his tenure, he contributed significantly to BD's key acquisitions and financial functions. His leadership has been pivotal for the company’s momentum, as he expressed confidence in BD’s capacity to drive shareholder value and affect patient lives positively.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced management will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, at 4:00 p.m. PT. The presentation will be accessible via BD's investor relations website and available for replay for at least seven days post-event. Related materials will be posted before the event starts. BD is a prominent global medical technology company focused on advancing health through innovative technology, supporting healthcare providers, and addressing global health challenges.
BD (Becton, Dickinson and Company) announced a remediation effort for the BD Alaris™ System, addressing issues related to a voluntary recall from February 4, 2020. Software version 12.1.2 will be released at no cost to customers to resolve software errors, including delay options programming and low battery alarm failures. While the remediation aims to enhance operational and cybersecurity aspects, it is important to note that this update has not yet been reviewed by the FDA. The company has also submitted a 510(k) application for regulatory clearance regarding the updates made to the product.
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021, with a record date of September 9, 2021. This sets the annual dividend rate at $3.32 per share, reflecting the company's commitment to delivering value to its shareholders. BD continues to be a leader in the medical technology sector, providing innovative solutions to enhance healthcare delivery globally.